BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Navarini L, Bisogno T, Margiotta DPE, Piccoli A, Angeletti S, Laudisio A, Ciccozzi M, Afeltra A, Maccarrone M. Role of the Specialized Proresolving Mediator Resolvin D1 in Systemic Lupus Erythematosus: Preliminary Results. J Immunol Res 2018;2018:5264195. [PMID: 30420970 DOI: 10.1155/2018/5264195] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Liu W, Huang J, Doycheva D, Gamdzyk M, Tang J, Zhang JH. RvD1binding with FPR2 attenuates inflammation via Rac1/NOX2 pathway after neonatal hypoxic-ischemic injury in rats. Exp Neurol 2019;320:112982. [PMID: 31247196 DOI: 10.1016/j.expneurol.2019.112982] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
2 Parashar K, Schulte F, Hardt M, Baker OJ. Sex-mediated elevation of the specialized pro-resolving lipid mediator levels in a Sjögren's syndrome mouse model. FASEB J 2020;34:7733-44. [PMID: 32277856 DOI: 10.1096/fj.201902196R] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
3 Wierenga KA, Strakovsky RS, Benninghoff AD, Rajasinghe LD, Lock AL, Harkema JR, Pestka JJ. Requisite Omega-3 HUFA Biomarker Thresholds for Preventing Murine Lupus Flaring. Front Immunol 2020;11:1796. [PMID: 32973753 DOI: 10.3389/fimmu.2020.01796] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
4 Chen W, Wang Q, Zhou B, Zhang L, Zhu H. Lipid Metabolism Profiles in Rheumatic Diseases. Front Pharmacol 2021;12:643520. [PMID: 33897433 DOI: 10.3389/fphar.2021.643520] [Reference Citation Analysis]
5 Callan N, Hanes D, Bradley R. Early evidence of efficacy for orally administered SPM-enriched marine lipid fraction on quality of life and pain in a sample of adults with chronic pain. J Transl Med 2020;18:401. [PMID: 33087142 DOI: 10.1186/s12967-020-02569-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Cheng T, Ding S, Liu S, Li X, Tang X, Sun L. Resolvin D1 Improves the Treg/Th17 Imbalance in Systemic Lupus Erythematosus Through miR-30e-5p. Front Immunol 2021;12:668760. [PMID: 34093566 DOI: 10.3389/fimmu.2021.668760] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Mehrotra P, Ravichandran KS. Drugging the efferocytosis process: concepts and opportunities. Nat Rev Drug Discov 2022. [PMID: 35650427 DOI: 10.1038/s41573-022-00470-y] [Reference Citation Analysis]
8 Li A, Zhang L, Li J, Fang Z, Li S, Peng Y, Zhang M, Wang X. Effect of RvD1/FPR2 on inflammatory response in chorioamnionitis. J Cell Mol Med 2020;24:13397-407. [PMID: 33025767 DOI: 10.1111/jcmm.15963] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
9 Liu T, Xiang A, Peng T, Doran AC, Tracey KJ, Barnes BJ, Tabas I, Son M, Diamond B. HMGB1-C1q complexes regulate macrophage function by switching between leukotriene and specialized proresolving mediator biosynthesis. Proc Natl Acad Sci U S A 2019;116:23254-63. [PMID: 31570601 DOI: 10.1073/pnas.1907490116] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 8.7] [Reference Citation Analysis]
10 Song J, Sun R, Zhang Y, Fu Y, Zhao D. Role of the Specialized Pro-resolving Mediator Resolvin D1 in Hashimoto's Thyroiditis. Exp Clin Endocrinol Diabetes 2021;129:791-7. [PMID: 33465800 DOI: 10.1055/a-1345-0173] [Reference Citation Analysis]
11 Yellepeddi VK, Parashar K, Dean SM, Watt KM, Constance JE, Baker OJ. Predicting Resolvin D1 Pharmacokinetics in Humans with Physiologically-Based Pharmacokinetic Modeling. Clin Transl Sci 2021;14:683-91. [PMID: 33202089 DOI: 10.1111/cts.12930] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Leuti A, Fazio D, Fava M, Piccoli A, Oddi S, Maccarrone M. Bioactive lipids, inflammation and chronic diseases. Adv Drug Deliv Rev 2020;159:133-69. [PMID: 32628989 DOI: 10.1016/j.addr.2020.06.028] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 23.0] [Reference Citation Analysis]
13 Li X, Bi X, Wang S, Zhang Z, Li F, Zhao AZ. Therapeutic Potential of ω-3 Polyunsaturated Fatty Acids in Human Autoimmune Diseases. Front Immunol 2019;10:2241. [PMID: 31611873 DOI: 10.3389/fimmu.2019.02241] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 10.0] [Reference Citation Analysis]
14 Gilley KN, Wierenga KA, Chauhuan PS, Wagner JG, Lewandowski RP, Ross EA, Lock AL, Harkema JR, Benninghoff AD, Pestka JJ. Influence of total western diet on docosahexaenoic acid suppression of silica-triggered lupus flaring in NZBWF1 mice. PLoS One 2020;15:e0233183. [PMID: 32413078 DOI: 10.1371/journal.pone.0233183] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]